HPβCD‑encapsulated Sophoricoside powder (~4.5% active payload). Soothing/brightening potential; use 0.5–5% complex (~0.023–0.225% active).

Encapsulated Sophoricoside is a cosmetic active provided as a Hydroxypropyl Beta‑Cyclodextrin (HPβCD) inclusion‑complex powder to improve handling, stability, and compatibility with aqueous systems.

Preclinical and mechanistic research on sophoricoside (a genistein‑glucoside from Styphnolobium/Sophora japonica) points to anti‑inflammatory activity in dermatitis models, mixed‑type tyrosinase inhibition (basis for brightening/spot care claims), and early hair‑growth signaling in dermal papilla cell studies. These signals support soothing, tone‑evening, and scalp‑care concepts; human clinical data for isolated sophoricoside remain limited and should be interpreted accordingly.

This encapsulated format delivers a 4.5% sophoricoside payload in a 95.5% HPβCD matrix. The dry, free‑flowing complex enhances dispersibility and is convenient for cool‑process addition to serums, creams/lotions, and masks while supporting gentle release.

Product Description: HPβCD inclusion complex of Sophoricoside presented as a white to off‑white, free‑flowing powder. Technical context and supporting evidence:

- Anti‑inflammatory support in atopic and contact dermatitis models (reduced epidermal thickening, mast‑cell infiltration, IgE, and key cytokines; suppression of pathogenic CD4⁺ T‑cell differentiation).

- Pigment control potential via reversible, mixed‑type tyrosinase inhibition with low IC₅₀ in enzyme/cell systems (mechanistic; not yet clinical).

- Hair/scalp relevance suggested by M4 muscarinic receptor activation in dermal papilla cells (early mechanistic signal; human trials pending).

- Wound‑healing/antioxidant benefits reported for S. japonica topical extracts (extract‑level context; specific contribution of isolated sophoricoside requires further study).

- Safety: published topical research to date did not flag notable dermal toxicity at research doses; comprehensive human safety data for isolated sophoricoside remain limited. Standard patch‑testing practice applies.

Usage: Brightening/spot‑care serums, tone‑evening creams/lotions, soothing/barrier‑support formulas, and scalp tonics/essences.

Mixing method:

- Add the complex as a dry powder into the water phase with gentle stirring; avoid high shear and high heat.

- For emulsions, disperse after initial hydration of gums/thickeners; process ≤40°C.

- Target finished formula pH ~4.5–6.5 typical for facial leave‑on systems; confirm stability and clarity case‑by‑case.

- Not oil‑soluble; incorporate via aqueous phase or pre‑disperse in water/glycerin.

Usage rate: 0.5–5% (complex). At 4.5% payload this delivers ~0.023–0.225% Sophoricoside active in the finished formula.

Product characteristics: White to off‑white, free‑flowing powder (HPβCD inclusion complex); mild characteristic odor.

Solubility: Dispersible in water phase; Sophoricoside is carried within HPβCD. Not oil‑soluble.

Storage: Store cool (15–25°C), dry, airtight, and protected from light. Close immediately after use.